INNOVIVA, INC. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
INNOVIVA, INC. (INVA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $10.02 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-02-25
- INNOVIVA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-12-31 was $10.02M.
- INNOVIVA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2025-09-30 was $0.00.
- INNOVIVA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-12-31 was $0.00.
- INNOVIVA, INC. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- INNOVIVA, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $10.02M, a 766.96% increase from fiscal 2024.
- INNOVIVA, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $1.16M.
- INNOVIVA, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- INNOVIVA, INC. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $3.32M.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2025-12-31 | $10.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $10.02M derived: sum of 2 quarters · filed 2026-02-25 | $10.02M 10-K · filed 2026-02-25 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $1.16M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $1.16M 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $1.16M 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | -$463.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 derived: sum of 3 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 |
| 2023-09-30 | $463.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $463.00K derived: sum of 2 quarters · filed 2024-11-06 | $463.00K 10-Q · filed 2024-11-06 | $463.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $0.00 10-Q · filed 2024-07-31 | $0.00 derived: sum of 3 quarters · filed 2025-02-26 | $34.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $34.00K derived: sum of 3 quarters · filed 2025-02-26 | $34.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $34.00K derived: sum of 2 quarters · filed 2025-02-26 | $34.00K derived: sum of 3 quarters · filed 2025-02-26 | $3.32M 10-K · filed 2025-02-26 |
| 2022-09-30 | $34.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $34.00K derived: sum of 2 quarters · filed 2023-11-01 | $3.32M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $3.29M 10-Q · filed 2023-08-02 | ||
| 2022-03-31 | $3.29M 10-Q · filed 2023-05-09 | |||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-27 | $0.00 10-Q · filed 2022-07-27 | ||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |